SuperworthBeyondSpring BYSI
Drug Manufacturers - General, Healthcare
$0.43
−3.15%
- Market cap
- $17.7M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/a
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $0
- Net margin
- n/a
- Free cash flow yield
- −94.5%
Revenue was $0 over the last twelve months.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| R&D | $721K | $829K | $622K | $472K | $874K+21% | $1M+21% | $1M+67% | $1.5M+212% | $1.1M+23% | $973K−3% |
| SG&A | $1.3M | $1.8M | $1.7M | $1.2M | $1.7M+30% | $947K−48% | $751K−57% | $1.1M−9% | $1.2M−33% | $758K−20% |
| −$2.1M | −$2.6M | −$2.4M | −$1.7M | −$2.6M+27% | −$1.9M−26% | −$1.8M−24% | −$2.6M+53% | −$2.2M−15% | −$1.7M−11% | |
| Pre-tax income | −$2.1M | −$2.7M | −$2.2M | −$1.8M | −$2.6M+23% | −$1.9M−30% | −$1.7M−23% | −$2.5M+37% | −$2.2M−16% | −$1.6M−11% |
| $0 | $0 | $0 | $96K | $20K | $22K | $26K | $22K−77% | $192K+860% | $100K+355% | |
| Net income | −$3.2M | −$4M | −$2.1M | −$1.7M | $4.5M | −$1.8M−55% | −$1.5M−28% | −$2.1M+24% | −$2.2M | −$849K−53% |
| n/a | −$0.04 | n/a | n/a | n/a | −$0.04+0% | n/a | n/a | n/a | −$0.02−50% |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest BeyondSpring's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BYSIBeyondSpring | $17.7M | n/m | n/a | n/a | n/m | n/a | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on BeyondSpring
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .